Natalia Kunst, PhD candidate at the University of Oslo, presented a CHDS lunchtime seminar on “What is the Value of Further Research on the 21-Gene Assay for Breast Cancer Management”.
Ms. Kunst discussed her comprehensive value of information analysis assessing the state of the evidence and quantifying uncertainty on the use of 21-gene assay Oncotype DX to guide adjuvant chemotherapy in women with early-stage breast cancer. Her study represents a real-world application of the value of information approach, illustrating how this powerful methodology can provide timely guidance on pressing clinical questions.
Learn more: Learn about decision science topics.
Related news: Machine Learning Seminar
Related news: Modeling Software Seminar